The Bristol-Myers drug called BMS-663513 is a CD137 antagonist, while the drug GTC is working on with the Mayo Clinic is a CD137 agonist. Same molecular target, but the two programs are otherwise unrelated.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.